Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00824720 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of a Glaucoma Drug Delivery System

A Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Vistakon Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
55
Enrollment target
4
Study locations

NCT00824720: Completed Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Vistakon Pharmaceuticals.

NCT00824720 is a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 55 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00824720, a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Vistakon Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
55 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.

Primary Outcome

This outcome measures visual acuity in logMARs. logMAR is the logarithm of the minimum angle of resolution (logMAR). The ideal is 0.0 and represents 20/20 Snellen acuity. logMar values \> 0.00 indicate vision poorer than the ideal and values \<0.00 indicate vision greater than the ideal.

Conditions Studied

Ocular Hypertension Glaucoma Open-Angle

Interventions

  • DEVICE Placebo Device
  • DRUG High Dose Device
  • DRUG Low Dose Device

Study Locations (4)

California

  • - Artesia

Kentucky

  • - Louisville

Maryland

  • - Baltimore

South Carolina

  • - Mt. Pleasant

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2008-12
Est. Completion 2009-04
Phase Phase 2
Vistakon Pharmaceuticals

13 total trials

What the finished NCT00824720 record still lists

NCT00824720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (80% lower).

The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo Device is the first listed.

NCT00824720 reports a single indexed study location in California, Kentucky, Maryland.

Frequently Asked Questions

What is clinical trial NCT00824720 about?

NCT00824720 is a clinical study titled "Safety and Efficacy of a Glaucoma Drug Delivery System". The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT00824720?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2008-12. Estimated completion is 2009-04.

What conditions does trial NCT00824720 study?

This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.

What interventions are being tested in trial NCT00824720?

The interventions under investigation include: Placebo Device (DEVICE), High Dose Device (DRUG), Low Dose Device (DRUG).

Who is sponsoring clinical trial NCT00824720?

This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00824720 being conducted?

This trial has 4 study locations across California, Kentucky, Maryland, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ocular Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00824720's enrollment target sits among peer trials

55 46th of 54 higher than 9 of 54 other Ocular Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00824720, the US trial registry maintained by the National Library of Medicine. NCT00824720 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.